{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:26:48Z","timestamp":1787218008921,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.medcli.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:35:21Z","timestamp":1700249721000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Extrahepatic manifestations of HCV where do we stand?"],"prefix":"10.1016","volume":"162","author":[{"given":"Mohamed Aly","family":"Mokhles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2023.10.011_bib0300","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/infdis\/162.2.569","article-title":"Hepatitis C virus in patients with cryoglobulinemia type II","volume":"162","author":"Pascual","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0305","first-page":"65","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"16","author":"Galossi","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11894-006-0064-y","article-title":"Extrahepatic manifestations of hepatitis C virus","volume":"8","author":"Sterling Richard","year":"2006","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.medcli.2023.10.011_bib0315","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2023.10.011_bib0320","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2893.1998.00097.x","article-title":"Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia","volume":"5","author":"Donada","year":"1998","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.medcli.2023.10.011_bib0325","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0330","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-117-7-573","article-title":"Hepatitis C virus infection in patients with essential mixed cryoglobulinemia","volume":"117","author":"Misiani","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0335","first-page":"1","article-title":"Miossec Pierre contribution of hepatitis C infection to a large cohort of cryoglobulin-positive patients: detection and characteristics","volume":"11","author":"Kolopp-Sarda Marie","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dld.2006.06.008","article-title":"Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0345","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11938-006-0006-7","article-title":"Treatment of hepatitis C cryoglobulinemia: mission and challenges","volume":"9","author":"Kayali","year":"2006","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0350","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.2006.03272.x","article-title":"Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia","volume":"147","author":"Sansonno","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"Suppl. 32","key":"10.1016\/j.medcli.2023.10.011_bib0355","first-page":"78","article-title":"HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies","volume":"21","author":"Ferri","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0360","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1191\/096120398678920091","article-title":"Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders","volume":"7","author":"Ferri","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2023.10.011_bib0365","doi-asserted-by":"crossref","first-page":"18544","DOI":"10.1073\/pnas.0509402102","article-title":"Activation of na\u00efve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders","volume":"102","author":"Rosa","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.medcli.2023.10.011_bib0370","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.medcli.2023.10.011_bib0375","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.10.011_bib0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/kel177","article-title":"Hepatitis C virus-associated B-cell proliferation\u2014the role of serum B lymphocyte stimulator (BLyS\/BAFF)","volume":"46","author":"S\u00e8ne","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0385","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.192.7.953","article-title":"Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response","volume":"192","author":"Do","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0390","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/ard.2007.085910","article-title":"The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders","volume":"68","author":"Landau","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0395","article-title":"SJBCL-2 gene family and the regulation of programmed cell death","volume":"59","author":"Korsmeyer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.medcli.2023.10.011_bib0400","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.510310230","article-title":"t(14; 18) translocation in chronic hepatitis C virus infection","volume":"31","author":"Zignego","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0405","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7326\/0003-4819-137-7-200210010-00008","article-title":"Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas","volume":"137","author":"Linda","year":"2002","journal-title":"Ann Inter Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0410","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood-2002-05-1537","article-title":"Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation","volume":"102","author":"Giannelli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.10.011_bib0415","first-page":"225","article-title":"Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia","volume":"21","author":"Ghinoi","year":"2004","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0420","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.57.12.728","article-title":"Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection","volume":"57","author":"Lee","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0425","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"328","author":"Johnson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0430","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1093\/jac\/dkx222","article-title":"Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy","volume":"72","author":"Bruzzone","year":"2017","journal-title":"J Antimicrob Chemotherapy"},{"key":"10.1016\/j.medcli.2023.10.011_bib0435","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjms.2017.03.007","article-title":"Hepatitis C treatment in patients with porphyria cutanea tarda","volume":"353","author":"Singal","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.medcli.2023.10.011_bib0440","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2017.02.037","article-title":"Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis","volume":"152","author":"Comarmond","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0445","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2023.10.011_bib0450","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/infdis\/jix517","article-title":"No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV","volume":"217","author":"Chaudhury","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0460","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000484237","article-title":"Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c","volume":"96","author":"Ikeda","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.medcli.2023.10.011_bib0465","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.15101","article-title":"Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection","volume":"49","author":"Su","year":"2019","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.medcli.2023.10.011_bib0470","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2023.10.011_bib0475","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","article-title":"Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis","volume":"67","author":"Cacoub","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2023.10.011_bib0480","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/apt.14845","article-title":"Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis","volume":"48","author":"Gragnani","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2023.10.011_bib0485","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2023.10.011_bib0490","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","article-title":"The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection","volume":"49","author":"El-Serag","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2023.10.011_bib0495","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2023.10.011_bib0500","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0505","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia","volume":"112","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102589","article-title":"Hepatitis C virus-related cryoglobulinemic vasculitis: a review of the role of the new direct antiviral agents (DAAs) therapy","volume":"19","author":"Mazzaro","year":"2020","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/j.medcli.2023.10.011_bib0515","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","article-title":"Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease","volume":"61","author":"Fabrizi","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2023.10.011_bib0520","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus peg-interferon-alpha\/ribavirin compared with peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.10.011_bib0525","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0530","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2015.09.003","article-title":"Successful treatment of HCV-associated cryoglobulinemia with ombitasvir\/paritaprevir\/ritonavir, dasabuvir and ribavirin: a case report","volume":"72","author":"Makara","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0535","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0540","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0545","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-127-6-199709150-00002","article-title":"Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma","volume":"127","author":"Zuckerman","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0550","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/10428190400007771","article-title":"Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature","volume":"45","author":"Morgensztern","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2023.10.011_bib0555","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1053\/j.gastro.2006.09.019","article-title":"Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH","volume":"131","author":"Nieters","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2023.10.011_bib0560","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C Virus Infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0565","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJM200311203492121","article-title":"Treatment of HCV-related mantle-cell lymphoma with Ribavirin and pegylated interferon alfa","volume":"349","author":"Levine","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.10.011_bib0570","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.23889","article-title":"Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study","volume":"90","author":"Michot","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2023.10.011_bib0575","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis","volume":"39","author":"Masarone","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2023.10.011_bib0580","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2023.10.011_bib0585","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","article-title":"Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"34","author":"Frigeni","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2023.10.011_bib0590","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1038\/bcj.2016.16","article-title":"Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C","volume":"6","author":"Lin","year":"2016","journal-title":"Blood Cancer J"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323006140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323006140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:57:43Z","timestamp":1758419863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775323006140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0025775323006140"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2023.10.011","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrahepatic manifestations of HCV where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}